{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:28:45Z","timestamp":1788805725495,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Global Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ijcard.2024.132714","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:05:10Z","timestamp":1730999110000},"page":"132714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A phenotypic comparison of the Romanian and French ATTRv cohorts: Glu54Gln founder pathogenic variant vs the most common variants in Western Europe"],"prefix":"10.1016","volume":"419","author":[{"given":"Gabriela","family":"Neculae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Zaroui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounira","family":"Kharoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"B\u00e9zard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Funalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Jercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorina","family":"Badelita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela","family":"Draghici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu","family":"Stan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra","family":"Jurcut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijcard.2024.132714_bb0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid [Internet]"},{"issue":"16","key":"10.1016\/j.ijcard.2024.132714_bb0010","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur. Heart J. [Internet]"},{"key":"10.1016\/j.ijcard.2024.132714_bb0015","series-title":"Screening for ATTR Amyloidosis in the Clinic: Overlapping Disorders, Misdiagnosis, and Multiorgan Awareness","first-page":"3","volume":"1","author":"Nativi-Nicolau","year":"2021"},{"issue":"2","key":"10.1016\/j.ijcard.2024.132714_bb0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2024.132714_bb0025","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10741-021-10098-6","article-title":"Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review","volume":"27","author":"Goyal","year":"2022","journal-title":"Heart Fail. Rev. [Internet]"},{"issue":"6","key":"10.1016\/j.ijcard.2024.132714_bb0030","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s10072-024-07311-3","article-title":"Validating the usefulness of Sudoscan in ATTRv: a single centre experience","volume":"45","author":"Moreno-Moraleda","year":"2024","journal-title":"Neurol. Sci. [Internet]"},{"issue":"12","key":"10.1016\/j.ijcard.2024.132714_bb0035","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","volume":"18","author":"Galderisi","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging [Internet]"},{"key":"10.1016\/j.ijcard.2024.132714_bb0040","series-title":"Definitions for a Common Standard for 2D Speckle Tracking Echocardiography: Consensus Document of the EACVI\/ASE\/Industry Task Force to Standardize Deformation Imaging","author":"Voigt","year":"2015"},{"issue":"5","key":"10.1016\/j.ijcard.2024.132714_bb0045","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jcmg.2016.05.007","article-title":"Early phase 99Tc-HMDP scintigraphy for the diagnosis and typing of cardiac amyloidosis","volume":"10","author":"Galat","year":"2017","journal-title":"JACC Cardiovasc. Imaging [Internet]"},{"key":"10.1016\/j.ijcard.2024.132714_bb0050","series-title":"Transthyretin Cardiac Amyloidosis in Continental Western Europe: An Insight Through the Transthyretin Amyloidosis Outcomes Survey (THAOS)","author":"Damy","year":"2019"},{"issue":"1","key":"10.1016\/j.ijcard.2024.132714_bb0055","article-title":"A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"18","author":"Gentile","year":"2023","journal-title":"Orphanet J. Rare Dis. [Internet]"},{"issue":"1","key":"10.1016\/j.ijcard.2024.132714_bb0060","first-page":"1","article-title":"Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population","volume":"15","author":"Jercan","year":"2020","journal-title":"Orphanet J. Rare Dis. [Internet]"},{"key":"10.1016\/j.ijcard.2024.132714_bb0065","article-title":"Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"10","author":"Waddington-Cruz","year":"2020","journal-title":"Neurol. Ther. [Internet]"},{"key":"10.1016\/j.ijcard.2024.132714_bb0070","first-page":"1","article-title":"Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"00","author":"Garcia-Pavia","year":"2024","journal-title":"J. Card. Fail."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132714_bb0075","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.acvd.2023.10.068","article-title":"Novel transthyretin variant linked to cardiac amyloidosis in the Romanian population","volume":"117","author":"Neculae","year":"2024","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"10","key":"10.1016\/j.ijcard.2024.132714_bb0080","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.acvd.2023.07.003","article-title":"Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France","volume":"116","author":"Damy","year":"2023","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132714_bb0085","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations*","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid [Internet]"},{"issue":"2","key":"10.1016\/j.ijcard.2024.132714_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000084299","article-title":"Extended phenotype in the transthyretin Tyr77 familial amyloid polyneuropathy","volume":"53","author":"Lossos","year":"2005","journal-title":"Eur. Neurol. [Internet]"},{"issue":"1","key":"10.1016\/j.ijcard.2024.132714_bb0095","article-title":"Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"19","author":"Gentile","year":"2024","journal-title":"PLoS One [Internet]"},{"key":"10.1016\/j.ijcard.2024.132714_bb0100","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: Where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr. Opin. Neurol. [Internet]"},{"issue":"4","key":"10.1016\/j.ijcard.2024.132714_bb0105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/acn3.51741","article-title":"Ser77Tyr transthyretin amyloidosis in Israel: initial manifestations and diagnostic features","volume":"10","author":"Dori","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ijcard.2024.132714_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13023-023-02933-w","article-title":"Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in-and out-patient databases","volume":"18","author":"Damy","year":"2023","journal-title":"Orphanet J. Rare Dis. [Internet]"},{"issue":"2","key":"10.1016\/j.ijcard.2024.132714_bb0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur. J. Heart Fail."},{"issue":"8","key":"10.1016\/j.ijcard.2024.132714_bb0120","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.ijcard.2024.132714_bb0125","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","author":"Brannagan","year":"2023","journal-title":"J. Am. Coll. Cardiol. [Internet]"},{"issue":"4","key":"10.1016\/j.ijcard.2024.132714_bb0130","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"Clin. Electrophysiol. [Internet]"},{"issue":"5","key":"10.1016\/j.ijcard.2024.132714_bb0135","doi-asserted-by":"crossref","first-page":"E003356","DOI":"10.1161\/CIRCGEN.121.003356","article-title":"Prevalence and outcomes of p.Val142Ile TTR amyloidosis cardiomyopathy: a systematic review","volume":"14","author":"Chandrashekar","year":"2021","journal-title":"Circ. Genom. Precis. Med. [Internet]"},{"issue":"1","key":"10.1016\/j.ijcard.2024.132714_bb0140","first-page":"1","article-title":"Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca","volume":"18","author":"Cisneros-Barroso","year":"2023","journal-title":"Orphanet J. Rare Dis. [Internet]"},{"issue":"15_supplement","key":"10.1016\/j.ijcard.2024.132714_bb0145","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.S5.007","article-title":"Variation of penetrance estimates in a wide spectrum of TTR-FAP families: implication for management of carriers (S5.007)","volume":"90","author":"Gorram","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ijcard.2024.132714_bb0150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur. J. Heart Fail. [Internet]"},{"issue":"2","key":"10.1016\/j.ijcard.2024.132714_bb0155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ejhf.3088","article-title":"Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: distinct from wild-type transthyretin amyloidosis?","volume":"26","author":"Razvi","year":"2024","journal-title":"Eur. J. Heart Fail. [Internet]"},{"issue":"15","key":"10.1016\/j.ijcard.2024.132714_bb0160","first-page":"28973","article-title":"Clinical penetrance of the transthyretin V122I variant in older black patients with heart failure: the SCAN-MP (screening for cardiac amyloidosis with nuclear imaging in minority populations) study","volume":"12","author":"Madhani","year":"2023","journal-title":"J. Am. Heart Assoc. [Internet]"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324013366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324013366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T21:30:01Z","timestamp":1736544601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324013366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"alternative-id":["S0167527324013366"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132714","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phenotypic comparison of the Romanian and French ATTRv cohorts: Glu54Gln founder pathogenic variant vs the most common variants in Western Europe","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132714","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"132714"}}